GLP-1 Use Among Young Children With Obesity in US Remains Rare but Is Rising Rapidly

SaxendaWegovyZepboundPositive

AI Analysis

Summary

GLP-1 weight loss drugs (Saxenda, Wegovy, Zepbound) are being prescribed to US children under 12 with obesity at increasing rates, though overall numbers remain low. Prescriptions increased 310-fold from 2019 to June 2026.

Importance:3/10

Sentiment:

0.30

GLP-1obesitypediatricprescription trendsmarket adoption

Related Companies

$NVO $LLY

Read the original article

Published by PR Newswire Biotech on September 4, 2026 10:12 AM

Read Original